- Home
- STR vs NVAX Comparison
STR vs NVAX Comparison
Compare STR & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STR
- NVAX
- Stock Information
- Founded
- STR 2016
- NVAX 1987
- Country
- STR United States
- NVAX United States
- Employees
- STR N/A
- NVAX N/A
- Industry
- STR Oil & Gas Production
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- STR Energy
- NVAX Health Care
- Exchange
- STR Nasdaq
- NVAX Nasdaq
- Market Cap
- STR 1.4B
- NVAX 1.3B
- IPO Year
- STR N/A
- NVAX 1995
- Fundamental
- Price
- STR $18.61
- NVAX $6.84
- Analyst Decision
- STR Buy
- NVAX Buy
- Analyst Count
- STR 6
- NVAX 5
- Target Price
- STR $25.60
- NVAX $16.60
- AVG Volume (30 Days)
- STR 1.5M
- NVAX 4.9M
- Earning Date
- STR 08-06-2025
- NVAX 08-07-2025
- Dividend Yield
- STR 7.83%
- NVAX N/A
- EPS Growth
- STR N/A
- NVAX N/A
- EPS
- STR 0.52
- NVAX 2.97
- Revenue
- STR $636,538,000.00
- NVAX $1,254,962,000.00
- Revenue This Year
- STR N/A
- NVAX $56.85
- Revenue Next Year
- STR N/A
- NVAX N/A
- P/E Ratio
- STR $35.71
- NVAX $2.30
- Revenue Growth
- STR 7.18
- NVAX 25.92
- 52 Week Low
- STR $14.58
- NVAX $5.01
- 52 Week High
- STR $25.64
- NVAX $17.81
- Technical
- Relative Strength Index (RSI)
- STR 50.57
- NVAX 51.12
- Support Level
- STR $17.60
- NVAX $6.54
- Resistance Level
- STR $18.37
- NVAX $7.20
- Average True Range (ATR)
- STR 0.57
- NVAX 0.28
- MACD
- STR -0.11
- NVAX 0.06
- Stochastic Oscillator
- STR 47.53
- NVAX 66.36
About STR Sitio Royalties Corp.
Sitio Royalties Corp is a pure-play mineral and royalty company. The group focuses on investing in mineral and royalty interests in the Permian and other productive U.S. oil basins.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.